| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Hypoxia/reoxygenation (H/R)-induced reduction in cell viability and increase in H9c2 cell apoptosis were dramatically counteracted by oxypaeoniflorin (OPA; 0.1-10 µM; 8 hours). By triggering the Sirt1 (Silent Information Regulator 2-related Enzyme 1)/Foxo1 (Forkhead Transcription Factor FKHR) signaling pathway in cardiac tissue and H9c2 cells, oxypaeoniflorin prevents cell death [1]. By modifying the Toll-like receptor (TLR), extracellular signal-related kinase (ERK), and p38 mitogen-activated protein (MAP) kinase signaling pathways in LPS-stimulated RAW264.7 cells impact, oxypaeoniflorin (0-30 μM) decreases inflammation[2].
|
|---|---|
| ln Vivo |
Treatment with oxypaeoniflorin (OPA; 10–40 mg/kg; intragastric injection; daily; for 30 days) can enhance fractional shortening (FS) and ejection fraction (EF) markers and dramatically lessen impairment to heart function. Myocardial infarction-related variables, such as cardiac troponin T (cTnT), cardiac troponin I (cTnI), and creatine kinase (CK-MB), can be greatly reduced by oxypaeoniflorin [1].
|
| Animal Protocol |
Animal/Disease Models: Myocardial ischemia/reperfusion (MI/R) injured C57BL/6 male mice (6-8 weeks old, 20-25 g) [1]
Doses: 10 mg/kg, 20 mg/kg, 40 mg/kg Route of Administration: intragastric (po) (po)administration; daily; for 30 days. Experimental Results: Dramatically diminished damage to cardiac function, and improved ejection fraction (EF) and fractional shortening (FS) indicators. |
| References |
|
| Additional Infomation |
Oxypaeoniflorin is a monoterpene glycoside with formula C23H28O12, isolated from several species of Paeoniae. It has a role as a plant metabolite. It is a cyclic acetal, a lactol, a bridged compound, a beta-D-glucoside, a 4-hydroxybenzoate ester and a monoterpene glycoside.
Oxypaeoniflorin has been reported in Paeonia lactiflora and Phellodendron amurense with data available. See also: Paeonia lactiflora root (part of); Paeonia veitchii root (part of); Paeonia X suffruticosa root bark (part of). |
| Molecular Formula |
C23H28O12
|
|---|---|
| Molecular Weight |
496.461228370667
|
| Exact Mass |
496.158
|
| CAS # |
39011-91-1
|
| PubChem CID |
21631105
|
| Appearance |
White to off-white solid powder
|
| Density |
1.7±0.1 g/cm3
|
| Boiling Point |
737.1±60.0 °C at 760 mmHg
|
| Flash Point |
254.6±26.4 °C
|
| Vapour Pressure |
0.0±2.5 mmHg at 25°C
|
| Index of Refraction |
1.708
|
| LogP |
-0.17
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
12
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
879
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)C5=CC=C(C=C5)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O
|
| InChi Key |
FCHVXNVDFYXLIL-WRJNSLSBSA-N
|
| InChi Code |
InChI=1S/C23H28O12/c1-20-8-22(30)13-6-23(20,33-18-16(28)15(27)14(26)12(7-24)32-18)21(13,19(34-20)35-22)9-31-17(29)10-2-4-11(25)5-3-10/h2-5,12-16,18-19,24-28,30H,6-9H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1
|
| Chemical Name |
[(1R,2S,3R,5R,6R,8S)-6-hydroxy-8-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-2-yl]methyl 4-hydroxybenzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~201.43 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (5.04 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0143 mL | 10.0713 mL | 20.1426 mL | |
| 5 mM | 0.4029 mL | 2.0143 mL | 4.0285 mL | |
| 10 mM | 0.2014 mL | 1.0071 mL | 2.0143 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
